{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-24-017807","form_type":"8-K","ticker":"ANGO","cik":"0001275187","company_name":"ANGIODYNAMICS INC","filed_at":"2024-04-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.678763+00:00","generated_at":"2026-06-04T02:11:34.065058+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"AngioDynamics Q3 pro forma sales up 8%; GAAP loss $4.73/sh on $159.5M goodwill impairment; guidance cut","bullets":["Reported net sales $75.2M; pro forma $66.0M (+8.0% YoY). GAAP net loss $190.4M ($4.73/sh) includes $159.5M goodwill impairment and $22.0M litigation settlement.","Pro forma gross margin 51.1% (-290bps); adj. loss per share $(0.16); adj. EBITDA -$3.6M.","Med Tech sales $25.7M (+12.6%); NanoKnife +46.7%, Auryon +14.7%. Med Device sales $40.3M (+5.2%).","Subsequent events: settled BD/Bard patent litigation; received FDA 510(k) clearance for AlphaVac in pulmonary embolism.","FY2024 guidance lowered: net sales $270-275M (prior $320-325M) due to divestiture/discontinuations; adj. loss per share $(0.54)-(0.58)."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-24-017807","json":"https://secwatch.observer/filing/0001140361-24-017807.json","markdown":"https://secwatch.observer/filing/0001140361-24-017807.md","text":"https://secwatch.observer/filing/0001140361-24-017807.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1275187/000114036124017807/0001140361-24-017807-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1275187/000114036124017807/ef20026031_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T02:11:34.065058+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"624bda47c545940febd6de6e0031a9c9ec2b6b4f","claim":"ANGIODYNAMICS INC reported financial results for the fiscal third quarter ended February 29, 2024.","evidence_excerpt":"On April 4, 2024, AngioDynamics issued a press release announcing financial results for the fiscal third quarter ended February 29, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1275187/000114036124017807/0001140361-24-017807-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal third quarter ended February 29, 2024"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}